Home / Learn / Immunotherapy / View All IO Resources

View All IO Resources

Here is a comprehensive list of all of our immuno-oncology resources. Enter your search terms in the box below to filter your results.

Displaying results 1 - 20 of 62

1 2 3 4 Next
March 1, 2021
The ACCC 47th Annual Meeting & Cancer Center Business Summit, March 1 – 5, 2021, will be a fully virtual experience that will deliver a focused look at the hot-button issues impacting your cancer program today, and the strategies you’ll need to emerge positioned for success tomorrow. AMCCBS Virtual will examine timely, real-world case studies from organizations that used the opportunity created …
Learn about the latest promising breakthroughs in immunotherapy, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.
Despite a century-long history and a substantial body of recent empirical evidence that attests to its clinical and economic effectiveness and improved access, telemedicine has yet to become a routine part of clinical practice for the majority of clinicians. If used appropriately, it can serve as an effective substitute for in-person care which does not require physical examination in nearly all facets …
Envision a day that cancer clinicians can ask an app to advise on immuno-oncology (IO) treatment options for a patient. That day may not be far off. Big data, deep analytics, and predictive modeling methods are transforming how cancer clinicians weigh treatment options.
SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies.
Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the immunotherapy care process.
Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.
Learn about the mental health implications of treatment with cancer immunotherapy, and how cancer care providers can better integrate mental health awareness into the IO care continuum.
April 16, 2020
Tammy Turner, Executive Director, Community Cancer Center, and Nancy Laney, President, Laney IT Consulting, discuss the most important strategies for planning, building, and implementing a telehealth program. (April 16, 2020)
April 9, 2020
Teri Bedard, BA, RT(R)(T), CPC, Director, Client Services, Revenue Cycle Coding Strategies LLC discusses CMS’ changes to telehealth coding and billing in response to the COVID-19 public health emergency, includes Q&A. (April 9, 2020)
Discover the results of the 2019 Trending Now in Cancer Care Survey—what tops the list of challenges, what areas are trending towards growth, and how cancer programs are evolving to meet the demands of 21st-century cancer care delivery.
How do interest specialists outside the field of oncology in participating in an inter-specialty immune-related adverse events (irAEs) tumor board? Cleveland Clinic discovered the key is to recruit physician champions who are not oncologists.
Johns Hopkins was one of the first institutions to use immunotherapies to treat intractable cancers. Because IO therapies can affect any of the body's organ systems, there was early recognition of the value of having a multidisciplinary team of organ specialists who could bring their expertise to the treatment of patients experiencing immune-related adverse events (irAEs).
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.
ACCC’s Immuno-Oncology Institute has developed the Survivorship Care Plans for Patients Receiving Immunotherapy as a resource for cancer programs and practices. and describes processes for developing survivorship care plans (SCPs) for patients treated with immunotherapy, effective practices in SCP design, and considerations for SCP delivery for this patient population.
December 9, 2019
With an increasing demand for cancer care services in a growing population, telemedicine and technology are becoming a vital component of delivering high-quality, value-based cancer care. Innovative e-health platforms and virtual navigation services can improve patient care by mitigating barriers for patients who are appropriate for cancer immunotherapy treatment, yet implementation of, and reimbursement …

Displaying results 1 - 20 of 62

1 2 3 4 Next